

Original Investigation

Ellagic Acid Enhances Antitumor Efficacy of Temozolomide in an *in vitro* Glioblastoma Model

Abdurrahman CETIN^{1*}, Burcu BILTEKIN²¹Health Sciences University, Gazi Yasargil Education and Research Hospital, Department of Neurosurgery, Diyarbakir, Turkey²Istanbul University, Cerrahpasa Faculty of Medicine, Department of Histology and Embryology, Cerrahpasa, Istanbul, Turkey

Corresponding author: Abdurrahman CETIN ✉ acetin2147@gmail.com

ABSTRACT

AIM: To observe the effect of combining ellagic acid (EA), a natural phenol present in fruits and vegetables, and temozolomide (TMZ) on the proliferation and expression profile of C6 glioma cell line.

MATERIAL and METHODS: Rat C6 glioma cells were treated with 100- μ M EA combined with 100 μ M TMZ for 24, 48, and 72 hours (h). Cell proliferation and p53 and caspase-3 protein levels were evaluated using immunocytochemistry. Multi drug resistance 1 (MDR1), O6-methylguanine-DNA methyltransferase (MGMT), and apoptotic protein (caspase-3 and p53) expressions were assessed using reverse transcription polymerase chain reaction (RT-PCR).

RESULTS: EA combined with TMZ conspicuously reduced the cell viability at all incubation times ($p < 0.001$). EA significantly downregulated MGMT expression regardless of the presence of TMZ even at early hours ($p < 0.001$). The combination therapy reduced MDR1 expression only on 48 h in comparison with TMZ alone. EA alone upregulated caspase-3 at 48 h but upregulated p53 at 48 and 72 h. The combined therapy enhanced the immunoreactivities of p53 and caspase-3 proteins independent of the treatment durations but not of the genes.

CONCLUSION: EA combined with TMZ may have a potential antiproliferative efficacy by inhibiting MGMT expression and activating apoptotic protein, p53 and caspase-3, expression.

KEYWORDS: Ellagic acid, Temozolomide, Glioma, MGMT

ABBREVIATIONS: **GBM:** Glioblastoma, **EA:** Ellagic acid, **TMZ:** Temozolomide, **MDR1:** Multi drug resistance 1, **MGMT:** O6-methylguanine -DNA methyltransferase, **RT-PCR:** Reverse transcription polymerase chain reaction, **BrdU:** 5-Bromo-2'-Deoxyuridine, **Nf-kB:** Nuclear factor kappa B

INTRODUCTION

Glioblastoma (GBM) is a common aggressive and malignant tumor that affects the central nervous system and has poor prognosis in children and adults (1). It generally spreads through the cerebrospinal fluid and metastasizes to normal brain tissues and the spinal cord, establishing a satellite tumor group around the primary tumor owing to its uncontrolled aggressive behavior and invasion ability (33). Although it can be managed by medical procedures such as surgery, radiation, and chemotherapy, the survival of patients

with malignant gliomas has been reported between 14 weeks (no treatment) and 40–50 weeks (1). This is because of high-grade gliomas, which generally show local recurrence (17). Thus, the development of innovative therapeutic strategies and more effective agents is urgently necessary to prolong the survival and improve quality of life of patients (35). Combinations of new agents with basic chemotherapeutics, which are highly efficacious and safe, are required to optimize the efficacy of cancer treatment, resulting in a more suitable choice for chemotherapy.

Combinations of chemical compounds, such as phenolic acids and flavonoids extracted from fruits and vegetables, may intensify the cytotoxic or antiproliferative effects of cancer therapeutic agents. A natural phenolic compound, ellagic acid (EA), is found in strawberries, walnuts, cranberries, raspberries, pecans, pomegranates, and other plant foods (16). EA has been claimed to have anticarcinogenic properties, which are mediated via cell cycle arrest, tumor formation and growth inhibition, and apoptosis induction (4), or via angiogenesis suppression (18). EA is generally used as a dietary supplement to decrease or prevent the risk of cancer. However, the effect of its combination therapy with common chemotherapeutic agents used in glioma is still unclear.

The current clinical management of GBM includes surgical resection combined with radiotherapy and chemotherapy. A DNA-alkylating agent, temozolomide (TMZ) is commonly used as a chemotherapeutic agent (7), which is a second-generation oral ketamine that readily penetrates the blood-brain barrier (34). TMZ has demonstrated its efficacy for GBM by attacking tumor cell DNA, damaging DNA by alkylation. However, multidrug resistance remains a primary obstacle in successfully treating GBM in humans (21,34). Therefore, it is suggested that therapies targeting the metabolic adaptation mechanisms and the multidrug-resistant genes of tumor cells may provide a synergistic effect in TMZ therapy. In fact, a number of preclinical studies have indicated that TMZ, in combination with inhibitors that target invasion mechanisms and cellular metabolism, decelerated tumor progression (7,34). To highlight the mechanism underlying the possible synergistic activity using EA, we investigated the effect of EA combined with TMZ on the drug resistance capacity, DNA repair mechanism, and apoptosis in C6 glioma cell line.

■ MATERIAL AND METHODS

Cell Culture

C6 glioma cells obtained from the American Type Culture Collection were cultured at 37°C in 95% humidified air with 5% CO₂ in Dulbecco's Modified Eagle Medium, supplemented with 10% fetal bovine serum, 100U/mL penicillin, and 100µg/mL streptomycin. The cells were subcultured every third day using trypsin. All concentrations are handled according to dose experiments as a range of 1, 10, and 100 µM for both EA and TMZ, determined using the doses described in literature (31,34). Accepted doses of EA (Sigma-Aldrich, E2250-10G, St. Louis, MO) and TMZ (Temozolid 20 mg, Dem İlaç, Istanbul, Turkey), both at 100-µM dose, were added to the media and the cells were incubated for 24, 48, and 72 hours (h). The cells were divided into four groups for every incubation time—the control, TMZ, EA, and EA combined with TMZ (EA+TMZ). All experiments were repeated for at least three times.

5-Bromo-2'-Deoxyuridine (BrdU) proliferation assay

BrdU proliferation assay was performed, according to the literature, based on immunohistochemistry (24). BrdU was purchased from Santa Cruz Biotechnology (SC-32323; Santa Cruz, CA); Histostain-Plus Bulk Kit was from SensiTekScyTek Laboratories (Utah, USA). Mouse monoclonal anti-BrdU

(Bu20A, SC-20045; Santa Cruz Biotechnology, Santa Cruz, CA) was used as the primary antibody (1:200, overnight). The aminoethylcarbazole (AEC) chromogen (SensiTekScyTek Laboratories, Utah, USA) was then applied. BrdU labeling was assessed by two researchers, and the proliferation index was calculated by evaluating at least 3000 cells and scored as a number of positively stained cells/total number of cells counted (24).

Immunohistochemistry

C6 glioma cells cultured on cover slips were incubated for 24 h; subsequently, groups of EA and TMZ were established. After 24-, 48-, and 72-h incubation periods, the experiments were ended at given durations and repeated three times. The cells were fixed with cold methanol for 5 minutes, and immunostaining was performed through indirect streptavidin immunoperoxidase method using an anti-polyvalent HRP Kit (SensiTekScyTek Laboratories, Utah, USA) to detect p53 and caspase-3 proteins. The cover slips were incubated overnight at 4°C with primary antibodies, namely, anti-p53 (orb136435; Biorbyt, California, USA) and anti-caspase-3 (active form, AB3623; Millipore, Darmstadt, Germany); these antibodies were diluted according to their protocols. The antigen-antibody complex was subsequently visualized using the AEC Substrate Detection System (SensiTekScyTek Laboratories, Utah, USA). The intensity of immunoreactivity was evaluated semi-quantitatively using H-SCORE analysis according to the literature (24).

Expression Analysis

Total RNA was extracted using Total RNA Purification Kit (Jena Bioscience, Germany) according to the kit protocol. cDNA was reverse-transcribed using the SCRIPT cDNA Synthesis Kit (Jena Bioscience, Germany), following the manufacturer's instructions. Real-time quantitative PCR (qPCR) was conducted in a CFX96 Touch (Bio-Rad, USA) machine using qPCR Green Master UNG (Jena Bioscience, Germany). Primer pairs were MDR1, F: 5'-CAGTTCATTCGCTCCTGACTAC-3' and R: 5'-CGTGCTGTAGCTGTCAATCT-3'; O6-methylguanine-DNA methyltransferase (MGMT), F: 5'-GAAGCCTATTC-CACGAACCT-3' and R: 5'-CACCTGTCTGGTGAAT-GAATCT-3'; p53, F: 5'-ACATGACTGAGGTGCTGAGA-3' and R: 5'-GATTCCTTCCACCCGGATAAG-3'; caspase-3, F: 5'-CTGACTGGAAAGCCGAAACT-3' and R: 5'-GTTC-CACTGTCTGTCTCAATACC-3'; glyceraldehyde 3-phosphate dehydrogenase (GAPDH), F: 5'-GCAAGGATACTGAGAG-CAAGAG-3'; and R: 5'-GGATGGAATTGTGAGGGAGATG-3'. After being normalized to GAPDH levels, the relative amount of MDR1, MGMT, p53, and caspase-3 transcripts in treated cells compared with controls were calculated as means ± standard error of the mean (SEM).

Statistical Analysis

Semi-quantitative and quantitative data from all groups were evaluated statistically by GraphPad InStat version 3.06 program (GraphPad Inc, CA, USA). All data were presented as the mean ± SEM. The mean of continuous variables was evaluated using the one way ANOVA, and variations between groups were compared using the Tukey-Kramer Multiple Comparison

Test. $p < 0.05$, $p < 0.01$, and $p < 0.001$ values were accepted as statistically significant.

RESULTS

Treatment with EA in combination with TMZ enhances inhibition of cell proliferation

To determine whether EA could potentiate the inhibitory effects of TMZ on the proliferation of C6 glioma cells, we, first, semi-quantitatively analyzed the effects of EA combined with TMZ and EA without TMZ by using BrdU proliferation assay. As shown in Figure 1, there is a significant suppression of cell proliferation activity in the group treated with EA alone in a time-dependent manner as compared with the control groups ($p < 0.001$). Moreover, combined treatment with EA and TMZ enhanced TMZ-mediated inhibition of cell proliferation

more significantly than treatment with TMZ alone ($p < 0.001$), independently of treatment time.

EA affects the apoptotic proteins of p53 and caspase-3 at protein level in a time-dependent manner, regardless of the presence of TMZ

To determine the apoptotic effects of EA on glioma cells, p53 and caspase-3 expressions were investigated through qPCR (Figure 2), and their protein levels were investigated through immunohistochemistry (Figure 3 and Figure 4). At 24 h, TMZ significantly upregulated p53 and caspase-3 expressions ($p < 0.001$) in the cells; however, EA significantly altered p53 expression only at 24 h ($p < 0.01$), only when combined with TMZ. In addition, EA with or without TMZ increased the reactivities of both proteins at all incubation times ($p < 0.001$). Although slight increases in p53 expression at 48 and




Figure 1: Microphotographs and graphical presentation of BrdU proliferation assay on C6 glioma cells treated with ellagic acid (EA) and temozolomide (TMZ); magnification: 400X.

a) $p < 0.001$ vs. all groups;
b) $p < 0.01$ vs. EA group;
c) $p < 0.001$ vs. control group;
d) $p < 0.001$ vs. TMZ group.

72 h in the combination groups were seen as compared with the control group, the differences were not significant. EA alone succeeded to upregulate *p53* expression at late

hours ($p < 0.001$), probably by mediating post-translational modifications. EA alone demonstrated a similar modification of *caspase-3* expression during the 48-h treatment ($p < 0.01$).




Figure 2: Graphical presentation of RT-PCR results of *p53* and *caspase-3* expressions on C6 glioma cells treated with ellagic acid (EA) and temozolomide (TMZ). **a)** $p < 0.001$ vs. all groups; **b)** $p < 0.01$ vs. control group; **c)** $p < 0.01$ vs. EA+TMZ group.




Figure 3: Microphotographs and graphical presentation of *p53* immunohistochemical results of C6 glioma cells treated with ellagic acid (EA) and temozolomide (TMZ); magnification: 400X. **a)** $p < 0.0001$ vs. control group; **b)** $p < 0.05$ vs. TMZ group.

EA combined with TMZ failed to downregulate MDR1 expression (ABCB1)

As a modulatory gene in drug resistance, *MDR1* (*ABCB1*) is often involved in the nonresponsive features of glioma cells (9). The present study investigated whether EA in combination with TMZ affected *MDR1* expression TMZ. The results indicated that treatment with EA alone and in combination with TMZ failed to reduce *MDR1* expression TMZ at longer incubations (Figure 5). In fact, its expression was upregulated significantly by EA only at 48 h ($p<0.001$), where as addition of TMZ suppressed this boosting effect and reduced its expression in the control levels. TMZ alone also showed an increased *MDR1* expression ($p<0.001$) at 48 h but not at 72 h, which suggests that only combined application of EA with TMZ may have an inhibitory effect in the multidrug resistance capacity of the C6 glioma cells at the early hours.

Ellagic acid downregulates the MGMT expression in a time-dependent manner regardless of the presence of TMZ

MGMT expression in EA-treated C6 glioma cells were investigated to determine whether *MGMT* expression, which is highly encountered in solid types of cancer and has proven to remove the drug-induced cytotoxic O6-alkylguanine DNA adducts, is regulated by EA. At 24 h, EA suppressed TMZ to induce *MGMT* overexpression ($p<0.001$) (Figure 6). Interestingly, at 48 and 72 h of incubation, EA down regulated *MGMT* expression dramatically whether combined with TMZ or not ($p<0.001$), suggesting that the antiproliferative properties of EA may be related to the modulatory effect of EA on *MGMT*.

DISCUSSION

Up to 95% of patients having GBM have been defeated by




Figure 4: Microphotographs and graphical presentation of caspase-3 immunohistochemical results of C6 glioma cells treated with ellagic acid (EA) and temozolomide (TMZ); magnification: 400X. **a)** $p<0.0001$ vs. control group; **b)** $p<0.05$ vs. TMZ group.




Figure 5: Graphical presentation of RT-PCR results of *MDR1* expression on C6 glioma cells treated with ellagic acid (EA) and temozolomide (TMZ) * $p < 0.05$ vs. control group; *** $p < 0.001$ vs. control group




Figure 6: Graphical presentation of RT-PCR results of *MGMT* expression on C6 glioma cells treated with ellagic acid (EA) and temozolomide (TMZ) **a)** $p < 0.001$ vs. control group; **b)** $p < 0.001$ vs. TMZ group

the disease and died within 5 years after initial diagnosis. Investigating novel strategies to treat GBM seems to be crucial, including targeting the metabolic adaptation mechanisms and utilizing combination therapies of chemotherapeutic drugs with inhibitors that target drug-resistant mechanisms or with various anti-inflammatory, antineoplastic, apoptotic, or toxic agents (5). Multiple targets for the emergence of drug-resistant tumors should aim to reduce the toxicity of chemotherapy and improve its efficacy (28). Research conducted on the synergistic properties of antitumor drugs gain attention so as to regulate apoptotic pathways, reverse multidrug resistance, inhibit tumor migration and invasion, and prevent angiogenesis system (3,6,14). In patient with

GBM, long-term use of TMZ is disadvantageous due to development of drug resistance, resulting in a reduced efficacy of TMZ in time (20). Thus, it is necessary to discover new therapeutic approaches in overcoming this obstacle such as developing combination therapies of naturally occurring dietary polyphenolic compound like EA. EA is known to have antioxidant, antifibrotic, and anticarcinogenic properties (27). Hence, we revealed the combining effect of EA with TMZ on the proliferation and expression profile of C6 glioma cell line.

Various studies have revealed that EA plays a significant role in inhibiting cell proliferation, preventing metastasis, and controlling tumor cell invasion. In a study by Wang et al., EA has shown to inhibit the cell viability, proliferation, and

invasion of human GBM cells, suggesting that the cell cycle arrest and DNA damage induced by EA may promote the inhibitory effects (30). EA has been demonstrated to reduce the prevalence of a variety of carcinogen-induced tumors (19), including distinctive anticarcinogenic effects in several types of cancers (4,19,29-31). Wang et al. also indicated that EA dramatically reduced the cell viability of GBM cells at the range of 25–200 μ M doses, suggesting its antiproliferative efficacy. Most importantly, EA downregulated anti-apoptotic protein (survivin and Bcl-2) expressions but elevated caspase-3 and pro-apoptotic protein Bax expressions in a dose-dependent manner (30). Another study showed that EA induced G1 arrest and apoptosis by p53-mediated activation in cells (10) while it inhibits angiogenesis by inactivating metalloproteinases (11). Additionally, TMZ was shown to significantly affect the apoptotic signal pathways in C6 cells by synergistic alteration with an antibiotic, by regulating Bax and procaspase-3 expressions (13). In the present study, TMZ significantly upregulated p53 and caspase-3 expressions at 24 h and increased the immunoreactivities of these proteins in cells at all incubation times. However, EA showed its activatory effect on p53 and caspase-3 expressions at longer incubation times, where as activatory effect on p53 protein levels was shown at all incubation durations. Combination with TMZ was only successful in inducing apoptotic p53 expression at 24h but not caspase-3 expression and other incubation times, although the protein levels of both were significantly elevated, suggesting a modulatory role of EA in the post-translational modifications.

More than 90% of treatment failure in aggressive metastatic cancers like GBM is due to drug resistance and multiple mechanisms (25,26). MDR pathways may be induced by elevated release of the drug from the cells to extracellular matrix, thereby reducing drug absorption in cancer cells (22). MDR characterized by increased p-glycoprotein expression may be a remarkable obstacle in treating cancer (8), as this is related to drug nonresponse in malignant tumors. *In vitro* studies have shown that untreated GBM principally express *MDR1* even if they are at least partially chemosensitive (12). One of them tested the chemosensitivity of GBM to some antineoplastic drugs on cultured tissue; it demonstrated *MDR1* expression in 16 sensitive and five highly resistant GBM cells (12). All of the 21 tumors identically expressed *p-glycoprotein*, suggesting that untreated GBM mostly express *p-glycoprotein*, which results in the existence of cell populations with early drug resistance in these tumors. This phenomenon may explain the disappointing overall long-term efficacy of chemotherapy. In the present study, we investigated whether EA in combination with TMZ modulates *MDR1* expression profile in C6 glioma cells. We found that EA failed to reduce *MDR1* expression alone or in combination with TMZ during longer incubation periods. In fact, its expression was upregulated significantly by EA only at 48 h, whereas addition of TMZ suppressed this boosting effect and reduced its expression, suggesting that only combined therapy of EA and TMZ may have an inhibitory effect at early hours in multidrug resistance capacity of the C6 glioma cells. High expression levels at 48 and 72 h is probably due to post-translational modulation by EA or adaptation of

cells to long incubation with EA, which may lead to drug resistance. This may be considered as a limitation of the present study.

GBM is resistant to some chemotherapeutic drugs because of the *MGMT* gene in glioma cells (23), which is highly expressed in solid types of cancer, resulting in the removal of the drug-induced cytotoxic O6-alkylguanine DNA adducts. This unique DNA repair protein, MGMT, has the ability to prevent the formation of DNA interstrand crosslinks in majority of human tumors, which are considered to be the critical lethal lesion induced by these drugs. The methylation status of MGMT promoter is a crucial indicator of the prognosis of GBM (2). There is an immediate need to develop well-tolerated drugs with the capacity to reverse drug resistance. In fact, various agents targeting drug resistance, with the capacity to mediate *MGMT* expression, are actively being studied. Therefore, we focused on the combination treatments of TMZ and EA in order to inhibit unforeseen DNA repair by mediating *MGMT* expression. We found that EA suppressed TMZ-induced *MGMT* over expression in a time-dependent manner, suggesting a modulatory effect of EA in combination with TMZ on *MGMT* expression. Additionally, since treatment of EA alone was able to inhibit *MGMT* expression, it may be considered that EA is able to show its antiproliferative feature by altering the DNA repair mechanism in C6 glioma cells.

Tumor cell invasion and metastasis result in an advanced tumor progression depending on the destruction to cell-cell and cell-matrix adhesion. Signaling pathways of some regulatory proteins like matrix metalloproteinases (MMPs) and transcription factors like nuclear factor kappa B (NF- κ B) are known to play crucial roles in tumor development through the transcriptional regulation of genes associated with tumor growth, invasion, and metastasis (13,32). Blocking the transcriptional activity of these proteins could inhibit glioma cell invasion; not being able to show a blocking effect of EA on one of the transcriptional and regulatory factor proteins in glioma cells is a limitation of our study. In a study by Luo et al., it was shown that down regulating a long non-coding RNA, namely, lncRNA UBE2CP3, could suppress glioma growth by regulating MMP9 protein expression *in vitro* and *in vivo*. They also hypothesized that lncRNA UBE2CP3 could affect the NF- κ B–MMP9 signaling pathway by mediating tumor necrosis factor receptor-associated factor 3 (TRAF3) interacting protein 2, which is an upstream regulator of both IKK/NF- κ B and JNK/AP-1 (15). Thus, in the future, we may focus on NF- κ B–MMP9 signaling pathway to show the relationship between modulatory and antiproliferative role of EA on glioma cells.

■ CONCLUSION

Taken together, the present study suggests that EA has antiproliferative and apoptotic activity in C6 glioma cell line that is mediated through the activation of p53 expression and the inhibition of *MGMT* expression. Long-term treatment with EA combined with TMZ may have an inhibitory effect on multidrug resistance capacity of the glioma cells and have a suppressing effect on DNA repair activity induced by TMZ in a time-dependent manner. This suggests a modulatory effect of

EA in combination with TMZ in cancer therapy. For including EA in the drug development and treatment protocols, more detailed and *in vivo* studies are required. Moreover, to develop a novel chemotherapeutic strategy to sensitize cancer cells to TMZ, the drug resistance of combination therapies involving chemotherapeutic agents in the treatment of GBM should be resolved.

■ REFERENCES

- Avgeropoulos NG, Batchelor T: New treatment strategies for malignant gliomas. *Oncologist* 4:209–224, 1999
- Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnoli F, Ermani M: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. *J Clin Oncol* 26(13): 2192–2197, 2008
- Domvri K, Zarogoulidis K, Zogas N, Zarogoulidis P, Petanidis S, Porpodis K, Kioseoglou E, Hohenforst-Schmidt W: Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer. *J Cancer* 8(18):3648–3656, 2017
- Edderkaoui M, Odinkova I, Ohno I, Gukovsky I, Go VL, Pandol SJ, Gukovskaya AS: Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. *World J Gastroenterol* 14(23):3672–3680, 2008
- Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU: Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. *Asian Pac J Cancer Prev* 18(1):3–9, 2017
- He Z, Xiao X, Li S, Guo Y, Huang Q, Shi X, Wang X, Liu Y: Oridonin induces apoptosis and reverses drug resistance in cisplatin resistant human gastric cancer cells. *Oncol Lett* 14(2):2499–2504, 2017
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 352(10):997–1003, 2005
- Hermann DM, Kilic E, Spudich A, Kramer SD, Wunderli-Allenspach H, Bassetti CL: Role of drug efflux carriers in the healthy and diseased brain. *Ann Neurol* 60:489–498, 2006
- Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB: Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). *Pharmacogenet Genomics* 21(3):152–161, 2011
- Khan N, Afaq F, Mukhtar H: Apoptosis by dietary factors: The suicide solution for delaying cancer growth. *Carcinogenesis* 28(2):233–239, 2007
- Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, Cass B, Bojanowski MW, Gingras D, Béliveau R: Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. *Carcinogenesis* 26(4):821–826, 2005
- Leweke F, Damian MS, Schindler C, Schachenmayr W: Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein. *Pathol Res Pract* 194(3):149–155, 1998
- Li X, Ling N, Bai Y, Dong W, Hui GZ, Liu D, Zhao J, Hu J: MiR-16-1 plays a role in reducing migration and invasion of glioma cells. *Anat Rec (Hoboken)* 296(3):427–432, 2013
- Li XQ, Ouyang ZG, Zhang SH, Liu H, Shang Y, Li Y, Zhen YS: Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction. *J Neurooncol* 119(1):91–100, 2014
- Luo Z, Pan J, Ding Y, Zhang YS, Zeng Y: The function and clinical relevance of lncRNA UBE2CP3-001 in human gliomas. *Arch Med Sci* 14(6):1308–1320, 2018
- Mertens-Talcott SU, Talcott ST, Percival SS: Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. *Journal of Nutrition* 133:2669–2674, 2003
- Moses MA, Brem H, Langer R: Advancing the field of drug delivery: Taking aim at cancer. *Cancer Cell* 4:337–341, 2003
- Narayanan BA, Geoffroy O, Willingham MC, Re GG, Nixon DW: p53/p21(WAF1/ CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. *Cancer Letters* 136:215–221, 1999
- Nijhoff WA, Peters WH: Quantification of induction of rat oesophageal, gastric and pancreatic glutathione and glutathione S-transferases by dietary anticarcinogens. *Carcinogenesis* 15(9):1769–1772, 1994
- Pinheiro R, Braga C, Santos G, Bronze MR, Perry MJ, Moreira R, Brites D, Falcão AS: Targeting gliomas: Can a new alkylating hybrid compound make a difference? *ACS Chem Neurosci* 8(1):50–59, 2017
- Salma S, Djan I, Bjelan M, Vulekovic P, Novakovic M, Vidovic V, Lucic M: Benefit and outcome of using temozolomide-based chemoradiotherapy followed by temozolomide alone for glioblastoma in clinical practice. *J BUON* 22(5):1233–1239, 2017
- Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W: Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. *Blood* 107(6): 2517–2524, 2006
- Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W: Mechanisms of chemoresistance to alkylating agents in malignant glioma. *Clin Cancer Res* 14: 2900–2908, 2008
- Soydas T, Yaprak Sarac E, Cinar S, Dogan S, Solakoglu S, Tuncdemir M, Kanigur Sultuybek G: The protective effects of metformin in an in vitro model of aging 3T3 fibroblast under the high glucose conditions. *J Physiol Biochem* 74(2):273–281, 2018
- Takara K, Sakaeda T, Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. *Curr Pharm Des* 12:273–286, 2006
- Thomas H, Coley HM: Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. *Cancer Control* 10:159–165, 2003

27. Thresiamma KC, Kuttan R: Inhibition of liver fibrosis by ellagic acid. *Indian J Physiol Pharmacol* 40(4):363-366, 1996
28. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M: Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. *Drug Resist Updat* 10(3):81-100, 2007
29. Umesalma S, Sudhandiran G: Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. *Eur J Pharmacol* 660:249-258, 2011
30. Wang D, Chen Q, Liu B, Li Y, Tan Y, Yang B: Ellagic acid inhibits proliferation and induces apoptosis in human glioblastoma cells. *Acta Cir Bras* 31(2):143-149, 2016
31. Wang D, Chen Q, Tan Y, Liu B, Liu C: Ellagic acid inhibits human glioblastoma growth in vitro and in vivo. *Oncol Rep* 37(2):1084-1092, 2017
32. Wild-Bode C, Weller M, Wick W: Molecular determinants of glioma cell migration and invasion. *J Neurosurg* 94:978-984, 2001
33. Zhang H, Ma L, Wang Q, Zheng X, Wu C, Xu BN: Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: A systematic review and meta-analysis. *Eur J Radiol* 83:2181-2189, 2014
34. Zhang R, Saito R, Shibahara I, Sugiyama S, Kanamori M, Sonoda Y, Tominaga T: Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells. *J Neurooncol* 126(2):235-242, 2016
35. Zhao J, Zhu J, Lv X, Xing J, Liu S, Chen C, Xu Y: Curcumin potentiates the potent antitumor activity of ACNU against glioblastoma by suppressing the PI3K/AKT and NF- κ B/COX-2 signaling pathways. *Onco Targets Ther* 10:5471-5482, 2017